Evidence map›Paper›PMID 40178307›Full record

ArticleAntimicrobial agents and chemotherapy2025

Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of

Aliaa Fouad, April M Bobenchik, Robin Chamberland, Andrew E Clark, Holly K Huse, Isabella W Martin, A Brian Mochon, Erik Munson, Maroun M Sfeir, Monica Srodon and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Aliaa FouadCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.ORCID 0009-0007-6467-1806
April M BobenchikDepartment of Pathology, Division of Clinical Pathology, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
Robin ChamberlandDepartment of Pathology, Saint Louis University, St. Louis, Missouri, USA.
Andrew E ClarkDepartment of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Holly K HuseDepartment of Pathology, Harbor-UCLA Medical Center, Torrance, California, USA.ORCID 0009-0004-7586-445X
Isabella W MartinDepartment of Pathology and Laboratory Medicine, Dartmouth Health, Lebanon, New Hampshire, USA.ORCID 0000-0001-7974-9767
A Brian MochonBanner Health, Phoenix, Arizona, USA.
Erik MunsonDepartment of Medical Laboratory Science, Marquette University, Milwaukee, Wisconsin, USA.
Maroun M SfeirDepartment of Pathology and Laboratory Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA.
Monica SrodonDepartment of Pathology, Eastern Connecticut Health Network, Manchester, Connecticut, USA.
Kimberly TaylorAmerican Health Associates Laboratory, Cincinnati, Ohio, USA.
Yungchou WangCape Regional Health System, Cape May Court House, New Jersey, USA.
Lars F WestbladeDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.
David P NicolauCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.ORCID 0000-0002-4148-0165
Tomefa E AsempaCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.ORCID 0000-0002-6268-0924

Funding

Pfizer
6 · The paper itself

Abstract

Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates (

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeCeftibutenEnterobacteriaceaeAmbulatory Care FacilitiesCefpodoximeCeftriaxoneCephalosporinsDrug CombinationsErtapenemHumansLevofloxacinMicrobial Sensitivity TestsNursing HomesOutpatientsAnti-Bacterial Agentsavibactamavibactam, ceftazidime drug combinationAzabicyclo CompoundsCefpodoximeCeftazidimeCeftibutenCeftriaxoneCephalosporinsDrug CombinationsErtapenemLevofloxacinceftibuten-avibactamEnterobacteralesoutpatient centers

Identifiers

PMID40178307
PMCPMC12057334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.